Medical Devices

Insulet unveils new data for its Omnipod 6 and a fully closed-loop system, signaling a major strategic push into the vast, untapped type 2 diabetes market.

Portable oxygen offers freedom, but as companies market summer travel, a closer look reveals that not all devices may deliver on their life-sustaining promise.

A recall of Target's popular baby wipes over dangerous bacteria raises critical questions about private label safety, supplier oversight, and consumer trust.

Zealand Pharma's petrelintide shows double-digit weight loss with remarkably few side effects, positioning it to challenge GLP-1 giants in the $100B market.

DBV Technologies heads to a key investor conference with its VIASKIN patch for peanut allergies. Can its science and strategy convince Wall Street?

Ottawa's new "AI for All" plan promises to revolutionize healthcare, but can its 'ironclad protections' keep pace with the technology it's unleashing?

As Pacira BioSciences fends off an activist investor, a high-stakes proxy fight pits long-term R&D against demands for short-term returns.

A new alliance between General Fluidics and Invetech seeks to move lab testing from centralized facilities to the clinic, promising faster, more accessible care.

A breakthrough biomarker, DNlite™, analyzes landmark trial data, offering a new way to identify high-risk diabetes patients missed by current standards.

FlackTek taps industry veteran Dustin Becker to lead global sales, a strategic move aimed at cementing its leadership in critical advanced manufacturing sectors.

With key regulatory decisions pending in Canada and the US, DIAGNOS's CARA AI platform is set to unlock a multi-billion dollar market for early eye disease detection.

Market research shows doctors are eager to prescribe Moleculin's new AML drug, Annamycin. It offers hope where there is none, but can the company survive to deliver it?

With 460,000 providers enrolled, Careviso is tackling healthcare's most hated process. A case study shows it's cutting case times by more than half.

BioCardia’s innovative cell therapy for heart failure receives a crucial FDA signal, potentially paving the way for a new treatment paradigm for millions.

Struggling biotech Tempest Therapeutics adds finance and medical heavyweights to its board. Is this a strategic reset or a last-ditch effort to survive?

Visure Solutions unveils Engineering Intelligence, a framework aiming to solve AI's context problem in regulated industries like aerospace and automotive.

A new class of doctor is bridging the gap between lab and patient. Meet the physician-scientists tackling deadly diseases with revolutionary new approaches.

A French firm is using a special economic zone to bypass China's tough regulations. Is its scarless vein treatment a medical breakthrough or a brilliant market hack?

Senté renewed its pact with a top scientist. We explore how deep scientific partnerships are becoming the key differentiator in a crowded, hype-filled market.

Swedish innovator Triomed AB unveils a system that triples ultrafiltration in peritoneal dialysis, tackling a critical patient risk and challenging market leaders.